

Preferred Drug List Announcement

MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) evaluation process. Drug/Drug classes for review for the upcoming quarter are identified at each of the quarterly meetings of the Drug Prior Authorization Committee and also posted on the Division's web page at <http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf> shortly following each meeting.

MO HealthNet Division's clinical team will conduct the clinical reviews of the drug products under evaluation each quarter. For preferred status consideration for your product, a more detailed review request should be presented to MHD. All clinical information for consideration should be forwarded to Joshua Moore at Joshua.S.Moore@dss.mo.gov or call (573) 751-6961. These submissions should generally follow the AMCP guideline format. Financial evaluations for these therapeutic class reviews are conducted by Conduent State HealthCare, LLC. Companies wishing to discuss opportunities for supplemental rebates should contact Conduent State HealthCare, LLC at (804) 965-8117.

If you have any questions concerning the PDL submission process, or the policy surrounding the process, feel free to contact the pharmacy program at MHD.ClinicalServices@dss.mo.gov or (573) 751-6961. If a public presentation is desired, please contact **Carmen Burton** at Carmen.M.Burton@dss.mo.gov or call (573) 751-6961. The Drug PA Committee will convene at **10:00 a.m. on Thursday, June 18, 2020.**

Drug Therapeutic Class Name

- Alpha-Glucosidase Inhibitors
- Amylin Analogs
- Antibiotics, GI Oral
- Antibiotics, Mupirocin Topical
- Antibiotics, Vaginal
- Antihyperuricemic Agents
- Benign Prostatic Hyperplasia Agents
- Biguanides and Combination Agents
- Bile Salt Agents
- Bone Ossification Agents, Bisphosphonates
- Cephalosporins
- Colony Stimulating Factors
- Cryopyrin-Associated Periodic Syndrome Agents
- DPP-IV Inhibitors and Combination Agents
- Duchenne Muscular Dystrophy Agents
- Electrolyte Depleters, Phosphate Lowering
- Electrolyte Depleters, Potassium Lowering
- Erythropoiesis Stimulating Agents
- Fluoroquinolones, Oral
- GI Antibiotics, Oral
- GLP-1 Receptor Agonists
- Growth Hormone Agents, Somatropin
- Growth Hormone and Growth Hormone Releasing Factors, Select Agents
- Idiopathic Pulmonary Fibrosis Agents
- Insulin, Long Acting
- Insulin, Mixed
- Insulin, Non-Analogs
- Insulin, Rapid Acting
- LHRH, GHRH Antagonists, Oral
- LHRH, GHRH Antagonists, Injectable
- Macrolides
- Meglitinides
- Methotrexate Agents
- Multiple Sclerosis Agents, Injectable
- Multiple Sclerosis Agents, Oral
- Neuromyelitis Optica Spectrum Disorder Agents
- Penicillins
- SGLT2 Inhibitors and Combination Agents
- Sick Cell Anemia Agents
- Sulfonylureas, Second Generation
- Targeted Immune Modulators, IL-6 Inhibitors
- Targeted Immune Modulators, IL17, 23, 12 Agents

- Targeted Immune Modulators, JAK Inhibitors
- Targeted Immune Modulators, Select Agents
- Targeted Immune Modulators, TNF Inhibitors
- Tetracyclines
- Thiazolidinediones and Combination Agents
- Thrombocytopenia Agents
- Urinary Tract Antispasmodics